The Regenerative Potential of Aqp2+ Progenitor Cells
Aqp2 祖细胞的再生潜力
基本信息
- 批准号:10716327
- 负责人:
- 金额:$ 50.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AdultAntibodiesBehaviorCell CountCell LineageCell SeparationCellsClassificationClone CellsDataData SetDefectDevelopmentDiseaseDistal convoluted renal tubule structureDuct (organ) structureEmbryoExhibitsFemaleFoundationsFutureGenerationsHistologicHumanHuman PathologyImmuneImmunofluorescence ImmunologicIn Situ HybridizationIn VitroInheritedInjuryIntercalated CellKidneyLabelLigandsLinkMaintenanceMediatingMolecular ProfilingMusNatural regenerationOrganoidsOsmolalitiesPathway interactionsPropertyPublishingRegenerative MedicineRegulationReportingResearchSex BiasSignal TransductionSolidStainsTamoxifenTechniquesTestingTherapeuticThymidineTissuesTransitional CellUreteral obstructionUrinary tract infectionWorkanalogbiomarker identificationcell typedaughter cellextracellularimprovedin vivoinjury and repairinnovationinsightkidney cellkidney fibrosismalenotch proteinnovelnovel markerregeneration potentialregenerativerepairedself-renewalsexsingle-cell RNA sequencingstem cell biologystem cellstranscriptometranscriptome sequencingvacuolar H+-ATPasewater channel
项目摘要
Abstract
Identification of renal progenitor cells holds promise for elucidating their contribution to developmental defects
and for isolating human renal progenitor cells as a prerequisite to evaluating their therapeutic potential.
Whether an adult kidney harbors progenitor cells is a hotly debated issue. Because mammalian kidneys can
regenerate new cells following normal shedding and injury, we have published a strict definition of an adult
renal progenitor cell requiring in vivo demonstration of 1) self-renewal, 2) clonogenicity, 3) multipotency, and
participation in 4) tissue maintenance and in 5) injury repair. We have identified a subset of Aqp2+ cells that
were also positively stained with an antibody recognizing both V-ATPase subunits B1 and B2 (Aqp2+B1B2+) as
the first potential candidate that strictly meets these 5 requirements. These Aqp2+ progenitor cells (AP)
exhibited the capacity of self-renewal, clonogenicity, and multipotency, and generated 5 types of cells including
principal cells (PC) and intercalated cells (IC) to form DCT2, CNT, and CD during development. Adult AP also
possessed these capabilities and regenerated all cell types in DCT2, CNT, and CD during tissue maintenance
and after unilateral ureteral obstruction (UUO). AP express IC-selective Jag1 and PC-selective Notch1, and
mediate repair correlating with Notch activation. Others have reported marked sex bias in the transcriptome
profile of PC. All of these findings have laid a solid foundation for this project. In this proposal, we propose to
test our central hypothesis that AP possess a unique molecular signature and their regenerative potential
differs between males and females and is regulated by Jag1. The specific Aims are to identify and validate the
AP's unique molecular signature (Aim 1), to investigate the AP's regenerative potential (Aim 2) and AP's
regulation by Jag1 (Aim 3) during tissue maintenance and during UUO-induced injury repair. We will explore a
combination of cutting edge techniques/approaches including RFP-based cell sorting to enrich Aqp2+ lineage
cells, single cell RNA-Seq, Aqp2ECE/+-based lineage tracing, unbiased thymidine analog labeling, and a set of
innovative tests that have been proven to be effective for vigorously validating B1B2 as a marker of AP.
Successful completion of the project will likely 1) reinforce AP as a novel concept, which differs from what has
been reported for the proximal tubules and could shed new light into the developmental, homeostatic, and
regenerative mechanisms; 2) yield deeper insights into the differential behavior of AP vs. PC and IC; 3) identify
and validate a unique molecular signature of AP for their isolation in the future; 4) link AP-mediated repair to
Notch signaling; 5) establish both sex and Jag1 as potential regulators of AP; and 6) answer many
fundamental questions regarding the origins of PC and IC, how these cells respond to injury through Notch,
and how disruption of this pathway leads to kidney fibrosis. In short, the findings are significant for human
pathology and stem cell biology in general, and for improvement of in vitro organoid generation.
摘要
肾祖细胞的鉴定有望阐明其对发育缺陷的贡献
以及用于分离人肾祖细胞作为评价其治疗潜力的先决条件。
成人肾脏是否含有祖细胞是一个激烈争论的问题。因为哺乳动物的肾脏
在正常脱落和损伤后再生新细胞,我们已经发表了一个严格的定义,
肾祖细胞需要体内证明1)自我更新,2)克隆形成,3)多能性,和
参与4)组织维护和5)损伤修复。我们已经鉴定了Aqp 2+细胞的一个子集,
用识别V-ATP酶亚基B1和B2的抗体(Aqp 2 + B1 B2+)也呈阳性染色,
第一个严格符合这五个要求的潜在候选人。这些Aqp 2+祖细胞(AP)
表现出自我更新、克隆形成和多能性的能力,并产生5种类型的细胞,包括
主细胞(PC)和嵌入细胞(IC)在发育过程中形成DCT 2、CNT和CD。成人AP
具有这些能力,并在组织维持期间在DCT 2、CNT和CD中再生所有细胞类型
单侧输尿管梗阻(UUO)后。AP表达IC选择性Jag 1和PC选择性Notch 1,并且
介导与Notch激活相关的修复。其他人报道了转录组中明显的性别偏见
PC的轮廓。所有这些发现都为该项目奠定了坚实的基础。在本提案中,我们建议
验证我们核心假设,即AP具有独特的分子特征及其再生潜力
在男性和女性之间存在差异,并由Jag 1调节。具体目标是确定和验证
AP独特的分子特征(Aim 1),以研究AP的再生潜力(Aim 2)和AP的
在组织维持期间和UUO诱导的损伤修复期间由Jag 1(Aim 3)调节。我们将探索一个
尖端技术/方法的组合,包括基于RFP的细胞分选以富集Aqp 2+谱系
细胞,单细胞RNA-Seq,基于Aqp 2 ECE/+的谱系追踪,无偏胸苷类似物标记,以及一组
创新的测试已被证明是有效的积极验证B1 B2作为AP的标志物。
该项目的成功完成可能会1)加强AP作为一个新的概念,它不同于
据报道,近端小管可以为发育、稳态和
再生机制; 2)对AP与PC和IC的差异行为产生更深入的了解; 3)识别
并验证AP的独特分子特征以用于将来的分离; 4)将AP介导的修复与
Notch信号传导; 5)建立性别和Jag 1作为AP的潜在调节因子; 6)回答许多
关于PC和IC起源的基本问题,这些细胞如何通过Notch对损伤做出反应,
以及这种途径的中断如何导致肾纤维化。总之,这些发现对人类具有重要意义。
病理学和干细胞生物学,以及用于改善体外类器官生成。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WENZHENG ZHANG其他文献
WENZHENG ZHANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WENZHENG ZHANG', 18)}}的其他基金
A novel urinary biomarker of diabetic nephropathy
糖尿病肾病的新型尿液生物标志物
- 批准号:
9192112 - 财政年份:2015
- 资助金额:
$ 50.93万 - 项目类别:
Epigenic Control of ENaC Transcription and Sodium Transport
ENaC 转录和钠转运的表观遗传控制
- 批准号:
8247094 - 财政年份:2009
- 资助金额:
$ 50.93万 - 项目类别:
Epigenic Control of ENaC Transcription and Sodium Transport
ENaC 转录和钠转运的表观遗传控制
- 批准号:
8039130 - 财政年份:2009
- 资助金额:
$ 50.93万 - 项目类别:
Epigenic Control of ENaC Transcription and Sodium Transport
ENaC 转录和钠转运的表观遗传控制
- 批准号:
7584209 - 财政年份:2009
- 资助金额:
$ 50.93万 - 项目类别:
Epigenic Control of ENaC Transcription and Sodium Transport
ENaC 转录和钠转运的表观遗传控制
- 批准号:
8436299 - 财政年份:2009
- 资助金额:
$ 50.93万 - 项目类别:
Epigenic Control of ENaC Transcription and Sodium Transport
ENaC 转录和钠转运的表观遗传控制
- 批准号:
8535426 - 财政年份:2009
- 资助金额:
$ 50.93万 - 项目类别:
Epigenic Control of ENaC Transcription and Sodium Transport
ENaC 转录和钠转运的表观遗传控制
- 批准号:
7769494 - 财政年份:2009
- 资助金额:
$ 50.93万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 50.93万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 50.93万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 50.93万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 50.93万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 50.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 50.93万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 50.93万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 50.93万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 50.93万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 50.93万 - 项目类别:














{{item.name}}会员




